Mene Pangalos, AstraZeneca EVP, BioPharmaceuticals R&D (via YouTube)
June 16, 2023 06:00 AM EDT
Deals
Bioregnum
China

As­traZeneca en­lists an up­start Chi­na biotech part­ner in the wake of an R&D set­back

John Carroll

Editor & Founder

One of the new­ly cre­at­ed biotech up­starts in Chi­na has tied up with a Big Phar­ma backer on a dis­cov­ery deal tar­get­ed at hy­per­c­ho­les­terolemia and …

Endpoints Premium

This article is available only to Premium subscribers

Upgrade to Premium for unlimited access and Premium exclusives.

UPGRADE
TRENDING NOW

Among phar­ma CEOs, the IRA now and the IRA lat­er get very dif­fer­ent re­ac­tions

Bris­tol My­ers restarts ra­dio­phar­ma­ceu­ti­cal Phase 3 tri­al, but de­lays read­out by one year

Up­dat­ed: With cost-cut­ting un­der­way, Bris­tol My­ers rais­es guid­ance, touts Phase 3 win and scraps an­oth­er

An­drew Left, short sell­er who cam­paigned against Valeant, is ac­cused of fraud by SEC

Eu­ro­pean drug reg­u­la­tor re­jects Alzheimer's drug Leqem­bi, cit­ing safe­ty con­cerns

sponsored

Crit­i­cal Junc­tures in Gene Ther­a­py Clin­i­cal Ma­te­r­i­al Man­u­fac­tur­ing: Where Do I Start? And Will It Work?

A service from the Financial Times